3 results
Approved WMOCompleted
The primary objective is to assess the clinical efficacy of siltuximab (a chimeric (murine-human) IgG1* mAb that specifically binds human IL-6 with high affinity and prevents its interaction with the IL-6 receptor, glycoprotein (GP) 80),…
Approved WMOCompleted
The primary objective is to investigate and compare the pharmacokinetic (PK) of MSB11022 acetate versus MSB11022-citrate in healthy subjects.
Approved WMOWill not start
* To evaluate the effect of different doses of TIP on the change in P. aeruginosa bacterial load in sputum as assessed by the change in colony forming units (CFUs) from baseline to Day 29 of treatment, each compared to placebo.* To assess the safety…